PLoS ONE (Jan 2022)

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021.

  • Kiersten J Kugeler,
  • John Williamson,
  • Aaron T Curns,
  • Jessica M Healy,
  • Leisha D Nolen,
  • Thomas A Clark,
  • Stacey W Martin,
  • Marc Fischer

DOI
https://doi.org/10.1371/journal.pone.0264179
Journal volume & issue
Vol. 17, no. 3
p. e0264179

Abstract

Read online

As of March 2021, three COVID-19 vaccines had been authorized by the U.S. Food and Drug Administration (FDA) for use in the United States. Each has substantial efficacy in preventing COVID-19. However, as efficacy from trials was 156 million fully vaccinated people. With high SARS-CoV-2 transmission and increasing numbers of people vaccinated in the United States, vaccine breakthrough infections will continue to accumulate. Understanding expectations regarding number of vaccine breakthrough infections enables accurate public health messaging to help ensure that the occurrence of such cases does not negatively affect vaccine perceptions, confidence, and uptake.